Analyzing Safety Data From Level Up
The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib.
Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatology. 2025;192:36-45.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Lisa Swanson, MD, FAAD
Eingun James Song, MD, FAAD, Co-CMO
Neal Bhatia, MD
Lisa Swanson, MD, FAAD
Brooke Jackson, MD
